[Update] Covid Early Treatment

COVID19 - CORONAVIRUS, 20 Sep 2021

Swiss Policy Research - TRANSCEND Media Service

19 Sep 2021 – Artemisia annua and arginine as promising covid early treatment options.

In view of non-durable covid vaccine protection, the availability of effective early treatment options for high-risk covid patients should remain a top public health priority.

Based on promising peer-reviewed pre-clinical and early clinical results, SPR has added artemisia annua and arginine to its covid early treatment protocol (see linked studies therein).

Concerning ivermectin, several positive studies turned out to be fraudulent or unreliable; if all low-quality studies are excluded, the benefit of ivermectin is no longer statistically significant. Some beneficial immuno-modulatory effect – as found by the French Institute Pasteur – is still plausible, but the available evidence has become rather uncertain.

The SPR Covid Early Treatment Protocol is available in English and in German.

As always, patients are asked to consult a doctor.

Related: Severe covid: a post-viral autoimmune attack (SPR)

See also:

• Covid early treatment
• The Ivermectin Debate
• Covid Vaccine Data

__________________________________________

Swiss Policy Research, founded in 2016, is an independent, nonpartisan and nonprofit research group investigating geopolitical propaganda in Swiss and international media. SPR is composed of independent academics that for personal and professional reasons prefer to protect their identities, and receives no external funding; there are no financial sponsors or backers. Our articles have been published or shared by numerous independent media outlets and journalists, among them Julian Assange, and have been translated into more than two dozen languages.

Go to Original – swprs.org

Share this article: email mastodon facebook 🔗 copy link

DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.

Comments are closed.